ZENEO® Adrenaline Needle-free adrenaline pre-filled autoinjector rescues you from an anaphylactic shock

Project Information

ZENEO

Grant agreement ID: 876000

DOI

10.3030/876000

Project closed

EC signature date 5 July 2019

Start date 1 August 2019

End date 30 November 2019

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost

€ 71 429,00

EU contribution

€ 50 000,00

Coordinated by

CROSSJECT
France

Periodic Reporting for period 1 - ZENEO (ZENEO® Adrenaline Needle-free adrenaline pre-filled autoinjector rescues you from an anaphylactic shock)

Reporting period: 2019-08-01 to 2019-11-30

Summary of the context and overall objectives of the project

Anaphylactic shock is a rare, severe and rapid onset allergic reaction that can be treated with the injection of Adrenaline, but if left untreated may cause death by asphyxia in 20 minutes. Adrenaline auto-injectors are needle-based pre-filled devices for self-injection into the muscle of the outer side of the thigh. User tests of some leading auto-injectors show a poor success rate after six weeks (42% or 43% depending on the auto-injectors), half of errors being that people do not wait long enough (above 3 seconds) while the needle injects inside the muscle.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

During the Feasibility Study period, Crossject finetuned the market approach and essential arguments, focusing on the market drivers and advantages versus current solutions and the cost to take ZENEO® Adrenaline to TRL9. A sales forecast for three years post-project was prepared based on market analysis.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

Crossject has used a combination of cutting-edge technologies to develop ZENEO® in such a way that it is capable of injecting a tiny jet of Adrenaline through a patient’s skin by propelling it at very high pressure and speed. All in all ZENEO® has been developed to relieve fear of needles; eliminate all risks of injury; and perform a true intramuscular injection by non-healthcare professionals due to its quick, one-handed use, thus excluding any risk of contamination and pollution of needles disposal. Crossject aims to be a leader of emergency use drug –device pharmaceutical products to save lives simply.

image1.png